EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines

Kumar Saurabh Srivastava iD, Vandana Jeswani, Nabanita Pal, Babita Bohra, Vaishali Vishwakarma, Atharva Ashish Bapat, Yamini Prashanti Patnaik, Navin Khanna, Rahul Shukla

Vaccines · 27.03.2023 · 11 (4) · 742

DOI: 10.3390/vaccines11040742 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 27.03.2023. Verfasst von Kumar Saurabh Srivastava und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Virus Research and Therapeutics, CSIR-Central Drug Research Institute, Lucknow 226031, India. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Science and Engineering Research Board (SERB)-Department of Science and Technology (DST), Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Japanese encephalitis virus (JEV) is the causal agent behind Japanese encephalitis (JE), a potentially severe brain infection that spreads through mosquito bites. JE is predominant over the Asia-Pacific Region and has the potential to spread globally with a higher rate of morbidity and mortality. Efforts have been made to identify and select various target molecules essential in JEV’s progression, but until now, no licensed anti-JEV drug has been available. From a prophylactic point of view, a few licensed JE vaccines are available, but various factors, viz., the high cost and different side effects imposed by them, has narrowed their global use. With an average occurrence of >67,000 cases of JE annually, there is an urgent need to find a suitable antiviral drug to treat patients at the acute phase, as presently only supportive care is available to mitigate infection. This systematic review highlights the current status of efforts put in to develop antivirals against JE and the available vaccines, along with their effectiveness. It also summarizes epidemiology, structure, pathogenesis, and potential drug targets that can be explored to develop a new range of anti-JEV drugs to combat JEV infection globally.

Schlagwörter

Stichwörter der Autor:innen

Japanese encephalitis (JE)Japanese encephalitis virus (JEV)antiviraldrugvaccine

Autor:innen und Institutionen

  • Division of Virus Research and Therapeutics, CSIR-Central Drug Research Institute, Lucknow 226031, India.
  • Translational Health, Molecular Medicine Division, International Centre for Genetic Engineering & Biotechnology, New Delhi 110067, India.

ORCID-Profile: Kumar Saurabh Srivastava

Förderung

  • The Science and Engineering Research Board (SERB)-Department of Science and Technology (DST), Government of India

Zitieren

APA

Srivastava, K. S., Jeswani, V., Pal, N., Bohra, B., Vishwakarma, V., Bapat, A. A., Patnaik, Y. P., Khanna, N., & Shukla, R. (2023). Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines. Vaccines, 11(4), 742. https://doi.org/10.3390/vaccines11040742

Vancouver

Srivastava KS, Jeswani V, Pal N, Bohra B, Vishwakarma V, Bapat AA, et al. Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines. Vaccines. 2023;11(4):742. doi:10.3390/vaccines11040742

BibTeX
@article{Srivastava2023,
  author = {Srivastava, Kumar Saurabh and Jeswani, Vandana and Pal, Nabanita and Bohra, Babita and Vishwakarma, Vaishali and Bapat, Atharva Ashish and Patnaik, Yamini Prashanti and Khanna, Navin and Shukla, Rahul},
  title = {Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {4},
  pages = {742},
  doi = {10.3390/vaccines11040742}
}
Kostenlos starten →